-
Je něco špatně v tomto záznamu ?
The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset patients
B. Stiburkova, K. Pavelcova, M. Pavlikova, P. Ješina, K. Pavelka,
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
AZV 15-26693 A, RVO00023728
Ministerstvo Zdravotnictví Ceské Republiky - International
RVO VFN64165
Ministerstvo Zdravotnictví Ceské Republiky - International
NV15-26693A
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
NLK
BioMedCentral
od 2003
BioMedCentral Open Access
od 2003
Directory of Open Access Journals
od 1999
Free Medical Journals
od 2003 do Před 6 měsíci
PubMed Central
od 2003
Europe PubMed Central
od 2003
ProQuest Central
od 2015-01-01
Open Access Digital Library
od 1999-10-01
Open Access Digital Library
od 1999-01-01
Open Access Digital Library
od 1999-01-01
Open Access Digital Library
od 2003-01-01
Medline Complete (EBSCOhost)
od 2011-01-01
Health & Medicine (ProQuest)
od 2015-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2003
Springer Nature OA/Free Journals
od 1999-06-01
- MeSH
- ABC transportér z rodiny G, člen 2 genetika MeSH
- alopurinol terapeutické užití MeSH
- antiuratika terapeutické užití MeSH
- dítě MeSH
- dna (nemoc) diagnóza farmakoterapie genetika MeSH
- dospělí MeSH
- febuxostat terapeutické užití MeSH
- frekvence genu MeSH
- genetická predispozice k nemoci genetika MeSH
- genotyp MeSH
- hyperurikemie diagnóza farmakoterapie genetika MeSH
- jednonukleotidový polymorfismus * MeSH
- kohortové studie MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- předškolní dítě MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Česká republika MeSH
BACKGROUND: ABCG2 is a high-capacity urate transporter that plays a crucial role in renal urate overload and extra-renal urate underexcretion. Previous studies have suggested an association between hyperuricemia and gout susceptibility relative to dysfunctional ABCG2 variants, with rs2231142 (Q141K) being the most common. In this study, we analyzed the ABCG2 gene in a hyperuricemia and gout cohort focusing on patients with pediatric-onset, i.e., before 18 years of age. METHOD: The cohort was recruited from the Czech Republic (n = 234) and consisted of 58 primary hyperuricemia and 176 gout patients, with a focus on pediatric-onset patients (n = 31, 17 hyperuricemia/14 gouts); 115 normouricemic controls were used for comparison. We amplified, sequenced, and analyzed 15 ABCG2 exons. The chi-square goodness-of-fit test was used to compare minor allele frequencies (MAF), and the log-rank test was used to compare empirical distribution functions. RESULTS: In the pediatric-onset cohort, two common (p.V12M, p.Q141K) and three very rare (p.K360del, p.T421A, p.T434M) allelic ABCG2 variants were detected. The MAF of p.Q141K was 38.7% compared to adult-onset MAF 21.2% (OR = 2.4, P = 0.005), to the normouricemic controls cohort MAF 8.5% (OR = 6.8, P < 0.0001), and to the European population MAF 9.4% (OR = 5.7, P < 0.0001). The MAF was greatly elevated not only among pediatric-onset gout patients (42.9%) but also among patients with hyperuricemia (35.3%). Most (74%) of the pediatric-onset patients had affected family members (61% were first-degree relatives). CONCLUSION: Our results show that genetic factors affecting ABCG2 function should be routinely considered in a hyperuricemia/gout diagnosis, especially in pediatric-onset patients. Genotyping of ABCG2 is essential for risk estimation of gout/hyperuricemia in patients with very early-onset and/or a family history.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20022835
- 003
- CZ-PrNML
- 005
- 20201214124846.0
- 007
- ta
- 008
- 201125s2019 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s13075-019-1860-8 $2 doi
- 035 __
- $a (PubMed)30894219
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Stiburkova, Blanka $u Institute of Rheumatology, Na Slupi 4, 128 50, Prague 2, Czech Republic. stiburkova@revma.cz. Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. stiburkova@revma.cz.
- 245 14
- $a The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset patients / $c B. Stiburkova, K. Pavelcova, M. Pavlikova, P. Ješina, K. Pavelka,
- 520 9_
- $a BACKGROUND: ABCG2 is a high-capacity urate transporter that plays a crucial role in renal urate overload and extra-renal urate underexcretion. Previous studies have suggested an association between hyperuricemia and gout susceptibility relative to dysfunctional ABCG2 variants, with rs2231142 (Q141K) being the most common. In this study, we analyzed the ABCG2 gene in a hyperuricemia and gout cohort focusing on patients with pediatric-onset, i.e., before 18 years of age. METHOD: The cohort was recruited from the Czech Republic (n = 234) and consisted of 58 primary hyperuricemia and 176 gout patients, with a focus on pediatric-onset patients (n = 31, 17 hyperuricemia/14 gouts); 115 normouricemic controls were used for comparison. We amplified, sequenced, and analyzed 15 ABCG2 exons. The chi-square goodness-of-fit test was used to compare minor allele frequencies (MAF), and the log-rank test was used to compare empirical distribution functions. RESULTS: In the pediatric-onset cohort, two common (p.V12M, p.Q141K) and three very rare (p.K360del, p.T421A, p.T434M) allelic ABCG2 variants were detected. The MAF of p.Q141K was 38.7% compared to adult-onset MAF 21.2% (OR = 2.4, P = 0.005), to the normouricemic controls cohort MAF 8.5% (OR = 6.8, P < 0.0001), and to the European population MAF 9.4% (OR = 5.7, P < 0.0001). The MAF was greatly elevated not only among pediatric-onset gout patients (42.9%) but also among patients with hyperuricemia (35.3%). Most (74%) of the pediatric-onset patients had affected family members (61% were first-degree relatives). CONCLUSION: Our results show that genetic factors affecting ABCG2 function should be routinely considered in a hyperuricemia/gout diagnosis, especially in pediatric-onset patients. Genotyping of ABCG2 is essential for risk estimation of gout/hyperuricemia in patients with very early-onset and/or a family history.
- 650 _2
- $a ABC transportér z rodiny G, člen 2 $x genetika $7 D000070997
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a alopurinol $x terapeutické užití $7 D000493
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a febuxostat $x terapeutické užití $7 D000069465
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a frekvence genu $7 D005787
- 650 _2
- $a genetická predispozice k nemoci $x genetika $7 D020022
- 650 _2
- $a genotyp $7 D005838
- 650 _2
- $a dna (nemoc) $x diagnóza $x farmakoterapie $x genetika $7 D006073
- 650 _2
- $a antiuratika $x terapeutické užití $7 D006074
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hyperurikemie $x diagnóza $x farmakoterapie $x genetika $7 D033461
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a jednonukleotidový polymorfismus $7 D020641
- 650 _2
- $a mladý dospělý $7 D055815
- 651 _2
- $a Česká republika $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Pavelcova, Katerina $u Institute of Rheumatology, Na Slupi 4, 128 50, Prague 2, Czech Republic. Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Pavlikova, Marketa $u Institute of Rheumatology, Na Slupi 4, 128 50, Prague 2, Czech Republic.
- 700 1_
- $a Ješina, Pavel $u Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
- 700 1_
- $a Pavelka, Karel $u Institute of Rheumatology, Na Slupi 4, 128 50, Prague 2, Czech Republic.
- 773 0_
- $w MED00007534 $t Arthritis research & therapy $x 1478-6362 $g Roč. 21, č. 1 (2019), s. 77
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30894219 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214124846 $b ABA008
- 999 __
- $a ok $b bmc $g 1595154 $s 1113511
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 21 $c 1 $d 77 $e 20190320 $i 1478-6362 $m Arthritis research & therapy $n Arthritis Res Ther $x MED00007534
- GRA __
- $a AZV 15-26693 A, RVO00023728 $p Ministerstvo Zdravotnictví Ceské Republiky $2 International
- GRA __
- $a RVO VFN64165 $p Ministerstvo Zdravotnictví Ceské Republiky $2 International
- GRA __
- $a NV15-26693A $p MZ0
- LZP __
- $a Pubmed-20201125